Sectors

  • Biotech

Research Coverage

  • Allogene Therapeutics, Inc. (ALLO)
  • Bicycle Therapeutics Plc (BCYC)
  • Geron Corporation (GERN)
  • Journey Medical Corp. (DERM)
  • Kymera Therapeutics, Inc. (KYMR)
  • MiNK Therapeutics, Inc. (INKT)
  • Mirati Therapeutics, Inc. (MRTX)
  • PDS Biotechnology Corporation (PDSB)
  • Rigel Pharmaceuticals, Inc. (RIGL)
  • Syndax Pharmaceuticals, Inc. (SNDX)
  • Viridian Therapeutics, Inc. (VRDN)

Biography

Kalpit Patel is a Biotech Analyst with B. Riley Securities responsible for covering emerging companies within the oncology and immunology sectors. He has 15 years of experience in the healthcare field.

Prior to joining B. Riley, Kalpit was a director at Oppenheimer covering early-stage biotech companies. He also spent several years as a pharmacist before embarking on a Wall Street career.

Kalpit is a registered pharmacist in Illinois. He received his MBA from The University of Chicago Booth School of Business and a Pharm.D. from the Massachusetts College of Pharmacy.

B. Riley Securities provides a full suite of investment banking, corporate finance, advisory, research, and sales and trading services. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, merger and acquisition (M&A) advisory, SPACs, corporate restructuring and recapitalization. B. Riley is nationally recognized and highly ranked for its proprietary small-cap equity research. B. Riley Securities formerly operated as B. Riley FBR following the merger of B. Riley & Co. and FBR & Co.